Skip to main content

Table 3 Timing and durability of symptom improvement

From: Fractionated stereotactic radiation therapy improves cranial neuropathies in patients with skull base meningiomas: a retrospective cohort study

Domain Median time to improve (mo.) Range (mo.) Durability of improve* Median time to worsening (mo.) (range) Range (mo.)
Visual Acuity/Field 3.2 0.1 - 30.1 92.7% 25.0 0.2 - 98.2
Diplopia/Ptosis 4.6 0.6 - 128.7 88.2% 47.0 0.5 - 85.9
Facial Sensation 4.8 0.6 - 58.6 93.3% 17.3 2.5 - 102.7
Facial Weakness 16.8 1.1 - 42.8 100% 33.3 1.9 - 64.9
Hearing -- 2.1 - 2.7 -- 5.1 2.5 - 82.8
Balance 2.4 2.8 - 2.8 100% 11.1 2.8 - 114.0
Tinnitus 2.8   100% 3.5 2.4 - 4.6
Cranial Nerve IX-XII 4.9 4.2 - 5.6 100% 24.6 6.4 - 31.5
Other 2.4 0.5 - 5.6 91.7% 9.5 2.4 - 20.3
  1. * Durability defined as percent of symptoms which after initial improvement remained improved over pre-radiation baseline at the time of last follow-up.